Clinical Efficacy & Immune Activation Demonstrated By Oncolytic Adenovirus ONCOS-102 In Solid Tumors

Time: 12:00 pm
day: Day One


  • Robust clinical activity of ONCOS-102 in combination with both anti-PD1 and chemotherapy has been observed in several solid tumor types
  • ONCOS-102 drives broad and persisting immune responses in responding patients
  • Extended dosing regimen drives stronger immune activation and increased systemic activity